Sanjay Jariwala - Biogen Senior Vice President - Worldwide Medical
| BIIB Stock | MXN 2,854 6.00 0.21% |
President
Dr. Sanjay Jariwala is Senior Vice President Worldwide Medical of the Company. Dr. Jariwala joins Biogen from AstraZeneca Pharmaceuticals, where he held the roles of Vice President, Head of Strategy and Vice President of Infection, Neuroscience, Autoimmunity and Antithrombotics, Global Medical Affairs. During his time at AstraZeneca, he led the transformation of the Worldwide Medical Affairs Council, developed a strategic medical planning process to align commercial operations and RD priorities, and created and established a new medical operating model for both medical strategy and execution at the global, regional, and local levels. Prior to AstraZeneca, Dr. Jariwala was Senior Vice President, Global Head of Business Development and a member of the Executive Committee at Vifor Pharma in Zurich, and prior to that at Aspreva Pharmaceuticals in Vancouver. His industry experience also includes several senior Medical Affairs and Clinical Development leadership roles at GlaxoSmithKline in the cardiovascular, metabolic, and urology therapy areas. Before moving to industry, he was a practicing physician for the National Health Service in the U.K since 2017.
| Tenure | 8 years |
| Phone | 617 679 2000 |
| Web | https://www.biogen.com |
Biogen Management Efficiency
The company has return on total asset (ROA) of 0.076 % which means that it generated a profit of $0.076 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2023 %, meaning that it generated $0.2023 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 14 records | PRESIDENT Age | ||
| Robert Telesmanic | Cognizant Technology Solutions | 56 | |
| Matthew Carey | The Home Depot | 58 | |
| TIMOTHY HOURIGAN | The Home Depot | 62 | |
| Mark Holifield | The Home Depot | 62 | |
| Srinivasan Veeraraghavachary | Cognizant Technology Solutions | 63 | |
| Timothy Rose | Costco Wholesale | 70 | |
| Edward Decker | The Home Depot | 60 | |
| James Murphy | Costco Wholesale | 70 | |
| Teresa Roseborough | The Home Depot | 64 | |
| William Deckelman | DXC Technology | 65 | |
| Richard McPhail | The Home Depot | 52 | |
| Ron Vachris | Costco Wholesale | 58 | |
| William Lennie | The Home Depot | 63 | |
| AnnMarie Campbell | The Home Depot | 57 | |
Management Performance
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 |
Biogen Inc Leadership Team
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Viehbacher, CEO Pres | ||
| Robin Kramer, Chief Accounting Officer, Vice President | ||
| Sanjay Jariwala, Senior Vice President - Worldwide Medical | ||
| Ginger Gregory, Chief Human Resource Officer, Executive Vice President | ||
| Anabella Villalobos, Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | ||
| Susan Esq, Chief VP | ||
| Michael CPA, Ex CFO | ||
| Natacha Gassenbach, Chief Affairs | ||
| Nicole Murphy, Head Technology | ||
| Michael Hencke, Head Relations |
Biogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 | |||
| Profit Margin | 0.28 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 861.61 B | |||
| Shares Outstanding | 144 M | |||
| Shares Owned By Insiders | 0.68 % | |||
| Shares Owned By Institutions | 89.99 % | |||
| Price To Earning | 169.05 X | |||
| Price To Book | 3.30 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Biogen Stock Analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.